Low-cost Aurolab aqueous drainage implant safe, effective for refractory childhood glaucoma
The effectiveness and safety profile of Aurolab aqueous drainage implant (AADI) are similar with published reports of the Baerveldt glaucoma implant (BGI) and Ahmed glaucoma valve implant in patients with refractory childhood glaucoma, making AADI a viable low-cost glaucoma drainage device (GDD), reports a recent study.
The investigators conducted a prospective interventional study in a tertiary care postgraduate teaching institute to assess the safety and efficacy of AADI, recruiting 31 children aged <16 years with uncontrolled intraocular pressure (IOP) refractory to medical treatment and considered at high risk of failure following trabeculectomy.
AADI was implanted to eligible children. Included in the analysis were those who completed a minimum of 6-month follow-up. Main clinical outcomes were IOP reduction from preoperative values and postoperative complications. A total of 34 eyes were analysed, with average follow-up of 18.3 months.
On maximum medication, mean IOP decreased from 27.4 mm Hg to 14.6 mm Hg at 1 week, 13.8 mm Hg at 6 months, 12.8 mm Hg, at 1 year (32 eyes of 29 children) and 14.7 mm Hg at 2 years (25 eyes of 22 children) postoperatively (p<0.001). The cumulative probability of success was 91.18 percent at 6 months and 81.7 percent at 18 to 24 months.
Mean number of topical medications dropped from 3.1 to 1.8 and 1.6 at 6 and 24 months, respectively (p<0.001). There were 25 patients who needed systemic acetazolamide preoperatively, decreasing to three patients at 2 years.
In addition, no tube erosion or infection was reported among patients. However, one eye developed retinal detachment, according to the investigators.